Back to Authors

Ouyang, Tianqui

Mayo Clinic

Massachusetts General Hospital

Citations 1

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T., Ann , Allegretti, Andrew S. , Cullaro, Giuseppe , Ouyang, Tianqui, Asrani, Sumeet K. , Przybyszewski, Eric M. , Robinson, Jevon E., Wadei, Hani M. , Hillien, Shelsea A. St., Saly, Danielle L. , Dageforde, Leigh Anne , Regner, Kevin R. , Belcher, Justin M. , Patidar, Kavish R. , Ma, Ann T , Ufere, Nneka N , Patidar, Kavish R , Asrani, Sumeet K , Wadei, Hani M , Cullaro, Giuseppe , Chung, Raymond T. , Wilechansky, Robert M. , Sharma, Pratima , Simonetto, Douglas A. , Jalal, Prasun K. , Orman, Eric S.

Alimentary Pharmacology & Therapeutics | July 16, 2024 | Volume: 60 | Issue: 6 | Pages: 778-786

10.1111/apt.18159 Get It

Summary Background & Aims The development of acute kidney injury (AKI) in the setting of alcohol‐associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown. Methods Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non‐AH groups. Results A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End‐stage Liver Disease‐Sodium (MELD‐Na) scores on admission. AKI phenotypes significantly differed between groups ( p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90‐day cumulative incidence of death (45% [95% CI: 39%–51%] vs. 38% [95% CI: 35%–40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90‐day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03–1.50], p = 0.024), but was not significant when adjusting for MELD‐Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90‐day mortality (sHR: 1.82 [95% CI: 1.16–2.86], p = 0.009). Conclusions Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90‐day mortality than those without AH, but this may have been driven by higher MELD‐Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.